Search

Your search keyword '"Denis M. Collins"' showing total 83 results

Search Constraints

Start Over You searched for: Author "Denis M. Collins" Remove constraint Author: "Denis M. Collins"
83 results on '"Denis M. Collins"'

Search Results

1. Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

2. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

3. Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

4. Abstract P3-07-16: Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models

5. Abstract P1-11-09: Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer

6. Abstract P1-11-10: Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

7. Abstract P6-12-09: Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines

8. Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

9. Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model

10. Supplementary Figure 5 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

11. Supplementary Figure 7 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

12. Data from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

13. Supplementary Figure 3 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

14. Supplementary Figure 8 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

15. Supplementary Tables 1-4 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

16. Supplementary Data Figure 1 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

17. Supplementary Figure 2 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

18. Supplementary Figure 6 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

19. Supplementary Figure 4 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

20. The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer

21. Abstract PS10-06: Comparative analysis of anti-proliferative effects and gene profiling of lapatinib, neratinib, and tucatinib

22. Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

23. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

24. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

25. Abstract P1-10-13: Examination of CCL26, CCL17 and CCL19 chemokines as biomarkers in HER2+ breast cancer (BC) in the neo-adjuvant setting

26. Abstract 3962: Development of selection-free HER4-mutated CRISPR/Cas9 knock-ins in cutaneous melanoma cell lines

27. Abstract P5-02-11: Immune cell profile of tumors from patients with metastatic (met) HER2+ breast cancer (BC) with < 30 months overall survival (OS)

28. Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines

29. Abstract 3333: Pre-clinical investigation of neratinib plus dasatinib in breast cancer

30. Abstract 3988: Identification of HER4 mutations with potential as biomarkers of response to neratinib

31. Research Strategies for Low-Survival Cancers

32. 274 ASSESSMENT OF THE ANTI-PROLIFERATIVE EFFECTS OF STANDARD CHEMOTHERAPY AND PAN-HER FAMILY TYROSINE KINASE INHIBITORS IN ESOPHAGEAL CANCER CELL LINE MODELS

33. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

34. Abstract P5-11-03: Tumor CXCL16/CXCR6 expression and soluble CXCL16 in HER2+ breast cancer (BC)

35. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

36. Abstract P4-06-19: The effect of relieving adenosine-mediated immunosuppression on trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) against HER2+ breast cancer cell lines

37. Abstract P4-21-27: Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

38. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer

39. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

40. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and

41. Acquired Resistance to Antibody-Drug Conjugates

42. Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

43. Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers

44. Abstract 951: The effect of neo-adjuvant chemotherapy on immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients

45. Anti-PD-1 responsive circulating immune cells as biomarkers of response to neoadjuvant chemotherapy in HER2+ breast cancer (BC)

46. Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

47. Innovative Technologies Changing Cancer Treatment

48. Preclinical evaluation targeting both IGF1R and IR in triple negative breast cancer

49. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

50. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines

Catalog

Books, media, physical & digital resources